Tripti Joshi (Editor)

H Michael Shepard

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
Name  H. Shepard

H. Michael Shepard wwwwarrenalpertorgsitesdefaultfilesimagesre
Education  University of California, Davis


H. Michael Shepard is an American cancer researcher.

He holds a bachelor's degree from the University of California, Davis. He received a Ph.D. from the Indiana University. Dr. Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University. He, is a founder, president and CSO of Receptor BioLogix, a California-based biopharmaceutical company focused on developing a newly discovered class of protein therapeutics called Intron Fusion Proteins (IFP) to treat cancer, autoimmune, metabolic and other diseases. Formerly, he was chief scientific officer and vice president of research at Canji, Inc., where he developed the application of the p53 gene product for cancer treatment. While at Genentech, he led the discovery and development of the breast cancer drug, Trastuzumab (trade name: Herceptin).

Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.

Dr. Shepard holds over 25 US patents.

Patents

  • U.S. Patent 7,138,388Methods to treat autoimmune and inflammatory conditions
  • U.S. Patent 7,105,156Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
  • U.S. Patent 6,946,259Compositions and methods for treating cells having double minute DNA
  • U.S. Patent 6,683,061Enzyme catalyzed therapeutic activation
  • U.S. Patent 6,551,585Use of tumor necrosis factor as an adjuvant
  • U.S. Patent 6,495,553Methods and compositions for overcoming resistance to biologic and chemotherapy
  • U.S. Patent 6,399,063Monoclonal antibodies directed to the HER2 receptor
  • U.S. Patent 6,387,371Monoclonal antibodies directed to the HER2 receptor
  • U.S. Patent 6,348,352Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
  • U.S. Patent 6,339,151Enzyme catalyzed therapeutic agents
  • U.S. Patent 6,333,169HER2 extracellular domain
  • U.S. Patent 6,331,524Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
  • U.S. Patent 6,245,750Enzyme catalyzed therapeutic agents
  • U.S. Patent 6,165,464Monoclonal antibodies directed to the HER2 receptor
  • U.S. Patent 6,159,706Application of enzyme prodrugs as anti-infective agents
  • U.S. Patent 6,015,567HER2 extracellular domain
  • U.S. Patent 5,851,991Therapeutic use of the retinoblastoma susceptibility gene product
  • U.S. Patent 5,837,520Method of purification of viral vectors
  • U.S. Patent 5,772,997Monoclonal antibodies directed to the HER2 receptor
  • U.S. Patent 5,720,954Monoclonal antibodies directed to the HER2 receptor
  • U.S. Patent 5,710,255Characterization of a novel anti-p110.sup.RB monoclonal antibody
  • U.S. Patent 5,677,171Monoclonal antibodies directed to the HER2 receptor
  • U.S. Patent 4,963,354Use of tumor necrosis factor (TNF) as an adjuvant
  • U.S. Patent 4,808,402Method and compositions for modulating neovascularization
  • References

    H. Michael Shepard Wikipedia


    Topics
     
    B
    i
    Link
    H2
    L